关节镜治疗髋臼盂唇损伤的疗效分析

目的评估关节镜下髋关节盂唇修复的临床疗效。方法选取63例关节镜下行髋关节盂唇撕裂修复患者,手术适应证为不同原因的腹股沟区疼痛伴或不伴机械症状,非手术治疗≥6个月无效;术前影像学检查及术中关节镜探查证实存在髋关节盂唇撕裂,且无关节炎病变(T?nnis≤1级)。发病时间0.5～11.0年,平均3.1年;随访时间12～36个月,平均26个月。采用改良Harris髋关节评分(MHHS)和髋关节功能评分(HOS)、日常生活髋关节功能评分(HOS-ADL)对疗效进行评估。结果 Cam撞击伴盂唇撕裂14例,Pincer撞击伴盂唇撕裂11例,混合型撞击伴盂唇撕裂27例,单纯盂唇撕裂11例,11例患者伴有髋臼软骨损伤。手术前后MHHS、HOS、HOS-ADL评分比较,差异有统计学意义(P<0.05)。结论对于无关节炎病变的髋撞击盂唇损伤患者,关节镜下治疗髋撞击、修复盂唇撕裂,有良好的效果;由于盂唇对于髋关节长期功能完整具有重要作用,建议尽可能进行盂唇缝合修复。

Comment on "Heterotopic ossification after arthroscopy for hip impingement syndrome"

We have read with great interest the article "Heterotopic ossification after arthroscopy for hip impingement syndrome" by Gao et al.[1] The authors showed the incidence of heterotopic ossification (HO) is an observed complication after hip arthroscopy for hip impingement syndrome which is not common (5.4%,13/242) and most HO has no or little effect on clinical symptoms.We also agree with them that oral nonsteroidal anti-inflammatory drugs (NSAIDs) are beneficial in the prevention of HO after primary hip arthroscopy.Although we agree with the conclusion similar to our previous studies in the clinic,there are some issues we like to comment on.